Page 863 - Cardiac Nursing

a
009
ar
39
Apt
2
9
9
/
6
0
g
9:0
1 P
Pa
M
9:0
p82
39
009
e 8
0
41.
3-8
3-8
41.
36_
d
qx
LWBK340-c36_p823-841.qxd 29/06/2009 09:01 PM Page 839 Aptara
LWB
LWB K34 0-c 36_ p82 3-8 41. qx d 2 9 / 0 6 / / 2 009 0 9:0 1 P M Pa g e 8 39 Apt ar a
K34
0-c
K34
2
C HAPTER 3 6 / Lipid Management and Cardiovascular Disease 839
19. Fletcher, B., Berra, K., Ades, P., et al. (2005). Management of abnormal 50. de Graaf, J., Hak-Lemmers, H., Hector, P., et al. (1991). Enhanced sus-
2
2
blood lipids: A collaborative approach. Circulation, 112, 3184–3209. ceptibility to in vitro oxidation of the low-density lipoprotein subfrac-
20. Castelli, W. P. (1996). Lipids, risk factors and ischaemic heart disease. tions in healthy subjects. Arteriosclerosis and Thrombosis, 11, 298–306.
4
Atherosclerosis, 124(Suppl.), S1–S9. 51. Reaven, G. M., Chen, Y, D., Jeppesen, J., et al. (1993). Insulin resistance
4
21. Schaefer, E. J., & Levy, R. I. (1985). Pathogenesis and management of and hyperinsulinemia in individuals with small, dense, low-density
lipoprotein disorders. New England Journal of Medicine, 312, lipoprotein particles. Journal of Clinical Investigation, 92, 141–146.
2
2
1300–1310. 52. Steinberg, D., Parthasarathy, S., Carew, T. E., et al. (1989). Beyond cho-
22. Gotto, A. M. (1983). High-density lipoproteins: Biochemical and meta- lesterol: Modification of low-density lipoprotein that increase its athero-
4
4
0
bolic factors. American Journal of Cardiology, 54(4), 2B–8B. genicity. New England Journal of Medicine, 320, 915–924.
0
23. Grundy, S. M. (1984). Hyperlipoproteinemia: Metabolic basis and ra- 53. Fraley A., & Tsimikas, S. (2006) Clinical applications of circulating oxi-
4
4
tionale for therapy. American Journal of Cardiology, 54, 20C–26C. dized low-density lipoprotein biomarkers in cardiovascular disease. Cur-
24. Grundy, S. M. (1984). Pathogenesis of hyperlipoproteinemia. Journal of rent Opinion in Lipidology, 17, 502–509.
7
7
5
5
Lipid Research, 25, 1611–1618. 54. Itabe, T. (2003). Oxidized low-density lipoproteins: What is understood
25. Breslow, J. L. (1992). The genetic basis of lipoprotein disorders: Intro- and what remains to be clarified. Biological & Pharmaceutical Bulletin,
6
6
duction and review. Journal of Internal Medicine, 231, 627–631. 26, 1–9.
26. Goldstein, J. L., & Brown, M. S. (1987). Regulation of low-density 55. Koschinsky, M. L. (2006). Novel insights into Lp(a) physiology and
lipoprotein receptors: Implication for pathogenesis and therapy of hy- pathogenicity: More questions than answers? Cardiovascular & Hemato-
6
6
6
6
percholesterolemia and atherosclerosis. Circulation, 76, 505–507. logical Disorders Drug Targets, 6, 276–278.
27. Gordon, D. J., Probstfield, J. L., & Garrison, R. J. (1989). High density 56. Lawn, R. M. (1992). Lipoprotein (a) in heart disease. Scientific American,
lipoprotein cholesterol and cardiovascular disease: Four prospective stud- 92(6), 54–60.
9
ies. Circulation, 79, 8–15. 57. Berglund, L., & Raakrishnan, R. (2004). Lipoprotein (a) An elusive car-
9
28. Kannel, W. B. (1983). High-density lipoproteins: Epidemiologic profile diovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology,
4
and risks of coronary artery disease. American Journal of Cardiology, 24, 2219–2226.
4
52(4), 9B–12B. 58. McConnell, J. P., & Hoefner, D. M. (2006). Lipoprotein-associated
6
6
29. Eisenberg, S. (1984). High-density lipoprotein metabolism. Journal of phospholipase A2. Clinical Laboratory Medicine, 26, 679–697.
5
5
Lipid Research, 25, 1017–1054. 59. Lanman, R. B., Wolfert, R. L., Fleming, J. K., et al. (2006). Lipoprotein-
30. Asztalos, B. F., & Schaefer, E. (2003). HDL in atherosclerosis: Actor or associated phospholipase A2: Review and recommendation of a clinical
9
bystander? Atherosclerosis Supplements, 4, 21–29.4 4 cut point for adults. Preventive Cardiology, 9, 138–143.
9
31. Joy, T., & Hegele, R. A. (2008). Is raising HDL a futile strategy for 60. Fair, J. M., & Berra, K. A. (1996). Endothelial function and coronary
7
7
atheroprotection? Nature Reviews, 7, 143–155. risk reduction: Mechanisms and influences of nitric oxide. Cardiovascu-
32. Soumain, S., Albrecht, C., Davies, A. H., et al. (2005). ABCA1 and ath- lar Nursing, 32, 17–22.
2
2
erosclerosis. Vascular Medicine, 10, 109–119. 61. Treasure, C. B., Klein, J. L., Weintraub, W. S., et al. (1995). Beneficial
0
0
33. Curtiss, L. K., Valenta, D. T., Hime, N. J., et al. (2006). What is so spe- effects of cholesterol-lowering therapy on the coronary endothelium in
cial about apolipoprotein AI in reverse cholesterol transport? Arterioscle- patients with coronary artery disease. New England Journal of Medicine,
6
6
rosis, Thrombosis and Vascular Biology, 26, 12–19. 332, 481–487.
2
2
34. Gotto, A. M. (1983). Clinical diagnosis of hyperlipoproteinemia. American 62. Levine, G. N., Keaney, J. F., & Vita, J. A. (1995). Cholesterol reduction
Journal of Medicine, 74(5A), 5–9. in cardiovascular disease. New England Journal of Medicine, 332,
4
4
35. Tall, A. R., & Small, D. M. (1978). Current concepts: Plasma high-den- 512–521.
9
9
sity lipoproteins. New England Journal of Medicine, 299, 1232–1236. 63. Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway
36. Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007). High-density for cholesterol homeostasis. Science, 232, 34–47.
2
2
8
lipoprotein as a therapeutic target. JAMA, 298, 786–798. 64. Austin, M. A., Brunzell, J. D., Fitch, W. L., et al. (1990). Inheritance of
37. Miller, N. E. (1990). HDL metabolism and its role in lipid transport. low density lipoprotein subclass patterns in familial combined hyperlipi-
0
European Heart Journal, 11, H1–H3. demia. Arteriosclerosis, 10, 520–530.
0
38. Rifkind, B. M. (1991). Drug treatment of hyperlipidemia. New York: Mar- 65. Grundy, S. M. (1998). Hypertriglyceridemia, atherogenic dyslipidemia,
cel Dekker. and the metabolic syndrome. American Journal of Cardiology, 81(4A),
39. deLemos, A. S., Wolfe, M. L., Long, C. J., et al. (2002). Identification of 18B–25B.
genetic variants in endothelial lipase in persons with elevated high- 66. Krauss, R. M. (1998). Atherogenicity of triglyceride-rich lipoproteins.
6
6
density lipoprotein cholesterol. Circulation, 106, 1321–1326. American Journal of Cardiology, 81(4A), 13B–17B.
40. Rader, D. J. (2003). Regulation of reverse cholesterol transport and clin- 67. National Cholesterol Education Program (NCEP): The Expert Panel.
ical implications. American Journal of Cardiology, 92(Suppl.), 43J–49J. (1993). Summary of the second report of the National Cholesterol Edu-
41. Cohen, J. C. (2003). Endothelial lipase: Direct evidence for a role in cation Program Expert Panel on Detection, Evaluation, and Treatment of
HDL metabolism. Journal of Clinical Investigation, 111, 318–321. High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA,
42. Ishida, T., Choi, S., Kundu, R. K., et al. (2003). Endothelial lipase is a 269, 3015–3023.
9
9
major determinant of HDL level. Journal of Clinical Investigation, 111, 68. Ordovas, J. M., Schaefer, E. J., Salem, D., et al. (1986). Apoprotein A-I
347–355. gene polymorphism associated with premature coronary artery disease
43. Navab, M., Ananthramaiah, G. M., Reddy, S. T., et al. (2005). The dou- and familial hypoalphalipoproteinemia. New England Journal of Medi-
4
4
ble jeopardy of HDL. Annals of Medicine, 37, 173–178. cine, 314, 671–677.
7
7
44. Ansell, B. J. (2007). Targeting the anti-inflammatory effects of high- 69. Zhang, L. H., Kamanna, V. S., Zhang, M. C., et al. (2008). Niacin in-
density lipoprotein. American Journal of Cardiology, 100(Suppl.), hibits surface expression of ATP synthase[BETA] chain in HepG2 cells:
9
9
3N–9N. Implications for raising HDL. Journal of Lipid Research, 49, 1195–1201.
45. Brown, B. G., Zhao, X. Q., Chait, A., et al. (1998). Lipid altering or an- 70. Grundy, S. M., Balady, G. J., Criqui, M. H., et al. (1997). Guide to the
5
tioxidant vitamins for patients with coronary disease and very low HDL primary prevention of cardiovascular diseases. Circulation, 95,
cholesterol? The HDL-Atherosclerosis Treatment Study design. Cana- 2329–2331.
4
dian Journal of Cardiology, 14, 6A–13A. 71. Smith, S. C., Jr., Blair, S. N., Criqui, M. H., et al. (1995). Preventing
4
2
46. Tall, A. R. (1998). Overview of reverse cholesterol transport. European heart attack and death in patients with coronary disease. Circulation, 92,
2
9
9
Heart Journal, 19, A31–A35. 2–4.
47. Assman, G., & Gotto, A. M. (2004). HDL cholesterol and protective 72. Smith, S., Allen, J., Blair, S., et al. (2006). AHA/ACC guidelines for sec-
factors in atherosclerosis. Circulation, 109(Suppl. III), 8–14. ondary prevention for patients with coronary and other atherosclerotic
48. Austin, M. D., Hokanson, J. E., & Brunzell, J. D. (1994). Characteriza- vascular disease: 2006 update. Circulation, 113, 2363–2372.
tion of low-density lipoprotein subclasses: Methodologic approaches and 73. Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation
clinical relevance. Current Opinion in Lipidology, 5, 395–403. of the concentration of low-density lipoprotein cholesterol in plasma, with
5
5
49. Gardner, C. D., Fortmann, S. P., & Krauss, R. M. (1996). Small low- the use of preparative ultracentrifuge. Clinical Chemistry, 18, 499–502.
8
8
density lipoprotein particles are associated with the incidence of coronary 74. U.S. Department of Health and Human Services. (1990). Recommenda-
artery disease in men and women. JAMA, 276, 875–881. tions for improving cholesterol measurement: A report from the Laboratory
6
6